Skip to content

Visual Outcomes With a Trifocal IOL in Subjects With Open-angle Glaucoma

Visual Acuity, Refractive Predictability, and Patient Reported Quality of Vision in Subjects Implanted With a Trifocal IOL With Stable Mild Open-Angle Glaucoma Undergoing Concurrent Minimally Invasive Glaucoma Surgery

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04619654
Enrollment
25
Registered
2020-11-06
Start date
2021-02-01
Completion date
2022-06-01
Last updated
2022-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cataract, Glaucoma, Open-Angle, IOL

Keywords

PanOptix, Trifocal IOL, Glaucoma, MIGS

Brief summary

This study will examine the visual outcomes of subjects undergoing cataract surgery and minimally invasive glaucoma surgery with the implantation of a trifocal intraocular lens.

Interventions

PROCEDURECataract surgery with implantation of trifocal IOL combined with trabecular scaffold

Cataract surgery with implantation of the PanOptix IOL combined with minimally invasive glaucoma surgery utilizing the Hydrus Microstent

Sponsors

Alcon Research
CollaboratorINDUSTRY
Vold Vision P.L.L.C
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Prospective single arm open label descriptive case series

Eligibility

Sex/Gender
ALL
Age
45 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Male or female subjects 45 years of age or older 2. A visually significant cataract 3. Diagnosis of mild OAG * Vertical C/D ratio of less than or equal to 0.8 * VF characteristics consistent with glaucoma with mean deviation not worse than -6.00 dB and without fixation threatening scotoma AND/OR with nerve abnormalities consistent with glaucoma (rim notching, rim thinning, disc hemorrhage, nerve fiber layer loss) * Medicated IOP 25 of less than or equal to mmHg on 1-3 medications * If treatment naïve (before glaucoma treatment) IOP between 21 and 35 mmHg 4. Glaucoma must be judged as stable by investigator based on review of subject medical records * Stable VF at least 1 year prior to surgery * Stable nerve fiber layer at least 1 year prior to surgery * IOP stable on current medication regimen at least 3 months prior to surgery 5. Shaffer grade of greater than III in all quadrants 6. Potential of good best corrected visual acuity at distance in the investigator's judgement of at least 0.1 logMAR (20/25) postoperatively 7. Able and willing to comply with follow up visits 8. Understands and signs the informed consent

Exclusion criteria

1. Previous incisional glaucoma surgery or cilio-ablative surgery 2. Prior laser trabeculoplasty within 90 days of surgery 3. Pseudoexfoliative, angle closure, uveitic, congenital, traumatic, angle recession, or neovascular glaucoma. 4. Moderate glaucoma with VF mean deviation between -6.00 dB and -12.00 dB 5. Severe and/or progressive glaucoma defined as * VF mean deviation worse than -12.00 dB * Consistent worsening of visual field on review of subject medical records * Consistent and progressive thinning of nerve fiber layer on review of subject medical records * Uncontrolled IOP on maximum glaucoma medications * Historically poor IOP control with medical therapy * Severe focal notching of the optic nerve rim * Expectation for future need of incisional glaucoma surgery 6. Ocular pathology or other medical condition which, in the investigator's judgment places the subject at increased risk of complications or significant vision loss during study period. 7. Ocular pathology that in the investigator's judgment may impact visual acuity postoperatively, i.e. significant ocular surface disease, corneal scarring, blepharitis, epiretinal membrane, macular degeneration, history of significant ocular trauma with sequela, etc. 8. Pregnant or breastfeeding women 9. Prior refractive surgery e.g. LASIK, RK, PRK, etc.

Design outcomes

Primary

MeasureTime frame
Mean Photopic Monocular Best Corrected Distance Visual Acuity (DCVA) (4 meters) logMAR3 months

Secondary

MeasureTime frame
Mean Photopic Monocular Uncorrected Intermediate Visual Acuity (UCIVA) (60 cm) logMAR3 months
Mean Photopic Binocular Best Distance Corrected Intermediate Visual Acuity (DCIVA) (60 cm) logMAR3 months
Mean Photopic Binocular Best Distance Corrected Near Visual Acuity (DCNVA) (40 cm) logMAR3 months
Mean Photopic Binocular Uncorrected Distance Visual Acuity (UCDVA) (4 meters) logMAR3 months
Mean Photopic Binocular Uncorrected Intermediate Visual Acuity (UCIVA) (60 cm) logMAR3 months
Mean Photopic Binocular Uncorrected Near Visual Acuity (UCNVA) (40 cm) logMAR3 months
Mean Photopic Binocular Best Corrected Distance Low Contrast Visual Acuity (25%) (4 meters) logMar3 months
Mean Mesopic Binocular Best Corrected Distance Low Contrast Visual Acuity (25%) (4 meters) logMar3 months
Mean Photopic Monocular Best Distance Corrected Intermediate Visual Acuity (DCIVA) (60 cm) logMAR3 months
Mean Photopic Monocular Best Distance Corrected Near Visual Acuity (DCNVA) (40 cm) logMAR3 months
Mean Photopic Monocular Uncorrected Distance Visual Acuity (UCDVA) (4 meters) logMAR3 months
Mean Photopic Monocular Uncorrected Near Visual Acuity (UCNVA) (40 cm) logMAR3 months
Mean Photopic Binocular Best Corrected Distance Visual Acuity (DCVA) (4 meters) logMAR3 months

Other

MeasureTime frameDescription
Quality of Vision Questionnaire (QoV)3 monthsGrading of dysphotopsia
Spectacle-Dependence questionnaire3 monthsGauging spectacle independence postoperatively
Mean preoperative IOP versus postoperative IOP3 months
Glaucoma Mean preoperative medications versus postoperative medications3 months
Percentage of patients with an IOP of less than or equal to18 mmHg and less than or equal to15 mm Hg on no glaucoma medications postoperatively3 months
Absolute Prediction Error3 monthsDifference from postoperative refraction from preoperative biometry
Mean Postoperative Refractive Spherical Equivalent3 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026